Synthetic Biology Global Market Report 2023: Diverse Applications of Synthetic Biology Bolsters Adoption
February 15, 2023 06:08 ET
|
Research and Markets
Dublin, Feb. 15, 2023 (GLOBE NEWSWIRE) -- The "Synthetic Biology Market?by Tools (Oligonucleotides, Enzymes, Synthetic Cells), Technology (Genome Engineering, Bioinformatics), Applications (Tissue...
Global Large Molecule Drug Substance CDMO Market Report 2022: Growing Cardiovascular Diseases (CVD) And CVD-Induced Deaths Bolsters Demand
January 31, 2023 10:58 ET
|
Research and Markets
Dublin, Jan. 31, 2023 (GLOBE NEWSWIRE) -- The "Global Large Molecule Drug Substance CDMO Market Size, Share & Industry Trends Analysis Report By Application (Mammalian, Microbial and Others), By...
Synlogic Announces Participation in Upcoming Investor and Industry Conferences
January 24, 2023 06:57 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced it will participate in the...
Synthetic Biology Market to record rapid growth with a CAGR of 25.4% during the forecast period, Technological Advancements and Growth Opportunities
January 23, 2023 08:23 ET
|
MAXIMIZE MARKET RESEARCH PRIVATE LIMITED
Pune, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Maximize Market research, a healthcare business research firm has published a report on the “Synthetic Biology Market”. The market report is a combination of...
Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection
January 19, 2023 11:39 ET
|
Pulmobiotics, S.L.
-- First ‘living medicine’ to treat antibiotic-resistant Pseudomonas aeruginosa infections in the lung, a leading cause of mortality in hospital settings – -- Data demonstrate treatment reduced lung...
Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)
January 19, 2023 06:58 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that SYNB1934 was granted...
Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results
January 09, 2023 09:00 ET
|
Telesis Bio
-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer...
Landkind Announces Preliminary Results from ISTO Clinical Study Showing LK-01™ Pure Salidroside Supports Oxygen Uptake and Mood state
January 05, 2023 09:00 ET
|
DoubleRainbow Biosciences
LEXINGTON, MASS., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landkind, a subsidiary of DoubleRainbow Biosciences leveraging advances in synthetic biology to deliver precision-engineered supplements to...
Synlogic Provides Corporate Update and Outlook for 2023
January 05, 2023 06:58 ET
|
Synlogic, Inc.
Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023 Rare Pediatric Disease Designation received for SYNB1353 for homocystinuria (HCU) Cash runway expected into H2 2024 ...
Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development
January 03, 2023 06:58 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through...